Dr. Joseph on Factors Influencing Frontline Therapy Selection in mRCC

Video

Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses considerations for frontline therapy selection in metastatic renal cell carcinoma (mRCC).

Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses considerations for frontline therapy selection for patients with metastatic renal cell carcinoma (mRCC).

The first thing that needs to be to be taken into consideration is a patient’s risk status, whether it’s good, intermediate, or poor. Risk status was initially designed to be prognostic, but can also be used to predict biology, adds Joseph.

In addition to risk status, a patient’s comorbidities should also be used to guide therapy selection. For example, if a patient has a cardiac history, is anti-VEGF therapy the best choice? Additionally, any soft or hard contraindication to immunotherapy could help eliminate an immunotherapy-based therapy from the equation. Ultimately, the decision comes down to good clinical judgement, concludes Joseph.

Recent Videos
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
© 2024 MJH Life Sciences

All rights reserved.